Mylan shares headed lower Friday amid news that Abbott Laboratories, Mylan’s largest shareholder, had sold a major chunk of its holdings.

Abbott sold 44 million shares at $41.60 per share on Thursday, according to a filing with the U.S. Securities and Exchange Commission. The move reduced the company’s holdings in Mylan to 25.8 million shares for a 4.8 percent stake, down from about 13 percent.

“We always said we did not intend to be long-term shareholders,” Abbott spokeswoman Darcy Ross said in an email. “We don’t like the volatility in the current market and determined this was a good time to sell some of our remaining shares.”

Abbott, based in Illinois, acquired Mylan’s shares in 2015 in exchange for a major portion of its generic drug business outside the U.S. Abbott said at the time it did not plan to be a long-term shareholder and would eventually sell its stake.

Advertise with us

The transaction with Abbott allowed Mylan to reincorporate in the Netherlands to lower its tax bill in a controversial maneuver known as an inversion. Mylan continues to be managed from its executive offices in Cecil.

Shortly after noon on Friday, Mylan’s shares were down 78 cents, or 1.9 percent, to $40.83.

Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.